Filing Flows › Neurocrine Biosciences (NBIX) › Q3 2026 › vs Q3 2025
Neurocrine Biosciences (NBIX) Q3 2026 vs Q3 2025 (year over year)
Neurocrine Biosciences's revenue rose $328M (+41%) from $795M in Q3 2025 to $1.1B in Q3 2026. Operating margin 29.5% against 30.1% (-0.6 pts).
Neurocrine Biosciences, Q3 2026: revenue $1.1B (+41% year over year), operating margin 29.5%, net earnings $206M, operating cash flow $395M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Operating margin | 29.5% | 30.1% | -0.6 pts |
| Net margin | 18.4% | 26.4% | -8.0 pts |
| Free cash flow margin | 34.2% | 27.0% | +7.2 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $1.1B | $795M | $328M | +41% |
| Operating profit | $331M | $239M | $92.3M | +39% |
| Costs & expenses | $791M | $556M | $236M | +42% |
| Pre-tax earnings | $284M | $292M | −$8.1M | -3% |
| Other expense, net | $47.6M | −$52.8M | $100M | — |
| Cost of revenue | $26.6M | $14.0M | $12.6M | +90% |
| Research & development | $352M | $250M | $102M | +41% |
| SG&A | $366M | $292M | $74.7M | +26% |
| Net earnings | $206M | $210M | −$3.0M | -1% |
| Income tax | $77.2M | $82.3M | −$5.1M | -6% |
| Depreciation & amortization | $44.0M | $7.7M | $36.3M | +471% |
| Share-based compensation | $54.3M | $53.7M | $600K | +1% |
| Working capital & other | $90.4M | −$43.4M | $134M | — |
| Operating cash flow | $395M | $228M | $168M | +74% |
| Free cash flow (OCF − capex) | $384M | $214M | $169M | +79% |
| Capital expenditures | $11.6M | $13.2M | −$1.6M | -12% |
Questions
How much did Neurocrine Biosciences's revenue grow year over year in Q3 2026?
Neurocrine Biosciences's revenue rose $328M (+41%) from $795M in Q3 2025 to $1.1B in Q3 2026. Operating margin 29.5% against 30.1% (-0.6 pts).